

## **Allergy Therapeutics**<sup>PLC</sup>

**Allergy Therapeutics plc**  
("Allergy Therapeutics" or the "Company")

### **Publication of Annual Report and Accounts Delayed Temporary Suspension of Shares**

**15 December 2023** Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, announces that its auditor, BDO LLP ("BDO"), has informed the Company that it requires additional time to complete its audit for the year ended 30 June 2023, due to resource availability within the audit engagement team.

As a result of the delay to the audit process, the Company will not meet the deadline to publish its annual report and accounts by 31 December 2023. Consequently, the Company is not able to comply with the requirements of AIM Rule 19 of the AIM Rules for Companies which requires publication of the Company's annual report and accounts within six months of the year end. Accordingly, the Company's ordinary shares will be suspended from trading on AIM with effect from 7.30 a.m. on 2 January 2024.

The Company's ordinary shares will remain temporarily suspended from trading on AIM until such time as the Company has satisfied the requirements of AIM Rule 19 with respect to publication of its annual report and accounts. The final audit and subsequent publication of Allergy Therapeutics' annual report and accounts are aiming to be completed as soon as possible, this is anticipated to occur by the end of January 2024.

For further information on the Company, please visit the website: [www.allergytherapeutics.com](http://www.allergytherapeutics.com).

This announcement contains inside information for the purposes of the UK Market Abuse Regulations.

- ENDS -

#### **For further information, please contact:**

##### **Allergy Therapeutics**

+44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

Shaun Furlong, Chief Financial Officer

##### **Panmure Gordon (Nominated Adviser and Broker)**

+44 (0) 20 7886 2500

Freddy Crossley, Emma Earl, Corporate Finance

Rupert Dearden, Corporate Broking

##### **ICR Consilium**

+44 20 3709 5700

Mary-Jane Elliott / David Daley / Davide Salvi

[allergytherapeutics@consilium-comms.com](mailto:allergytherapeutics@consilium-comms.com)

#### **Notes for editors:**

##### **About Allergy Therapeutics**

Allergy Therapeutics is an international commercial biotechnology company, headquartered in the UK, focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development includes vaccines for grass, tree, house dust mite and peanut. For more information, please see [www.allergytherapeutics.com](http://www.allergytherapeutics.com).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

ACSFLSFFRLELIV